中国新药杂志

正电子发射计算机断层显像技术在药物成瘾机制研究中的应用进展

PDF下载

王舒哲 ¹^,² , 王雁 ² , 黄芳华 ³ , 邱云良 ²

中国新药杂志 | 重大新药创制专项巡礼 2021,30(18): 1661-1667

收起

中国新药杂志 |重大新药创制专项巡礼 2021 , 30 (18) : 1661 -1667

正电子发射计算机断层显像技术在药物成瘾机制研究中的应用进展

全屏

王舒哲¹^,², 王雁², 黄芳华³, 邱云良²

作者信息

¹上海工程技术大学化学化工学院，上海　201620

²中国医药工业研究总院国家上海新药安全评价研究中心，上海　201203

³国家药品监督管理局药品审评中心，北京　100038

通讯作者:

黄芳华，女，博士，主要从事新药药理毒理审评工作。联系电话：（010）85243169，E-mail：huangfh@cde.org.cn。

邱云良，男，研究员，主要从事新药临床前评价研究。E-mail：ylqiu@ncdser.com。

作者简介:

王舒哲，女，硕士研究生，主要从事新药临床前依赖性评价研究。E-mail：wangsz318@163.com。

Application progress of PET in the study of drug addiction mechanism

Shu-zhe WANG¹^,², Yan WANG², Fang-hua HUANG³, Yun-liang QIU²

Affiliations

¹College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China

²National Shanghai Center for New Drug Safety Evaluation and Research, China State Institute of Pharmaceutical Industry, Shanghai 201203, China

³Center for Drug Evaluation, National Medical Products Administration, Beijing 100038, China

出版时间: 2021-09-30

文章导航

摘要

收起

药物成瘾是当前世界上最严重的公共卫生问题之一，目前认为药物成瘾是一种慢性、复发性的脑部疾病。对药物成瘾的确切机制，目前尚未完全阐明。分子影像技术的发展和各种显像剂的合成为人们认识药物成瘾的神经药理学机制提供了很大帮助。本文综述了正电子发射计算机断层显像（PET）在药物成瘾机制研究中的应用，重点总结了使用PET活体成像技术监测药物成瘾过程中神经递质的受体、受体转运蛋白、局部脑血流和脑葡萄糖代谢变化，从而了解药物成瘾的神经生物学基础，为寻找有效的治疗措施提供理论基础。

关键词

药物成瘾 / 机制 / 正电子发射计算机断层显像技术 / 显像剂

Abstract

收起

Drug addiction is one of the most serious public health problems in the world. At present, drug addiction is considered as a chronic and recurrent brain disease. The exact mechanism of drug addiction has not been fully elucidated. The development of peddler imaging technology and the synthesis of various imaging agents have provided great help for people to understand the neuropharmacological mechanism of drug addiction. This paper reviews the application of positron emission tomography (PET) imaging in the study of drug addiction mechanism, focusing on the monitoring of neurotransmitter receptors, receptor transporters, regional cerebral blood flow and cerebral glucose metabolism in the process of drug addiction by using PET in vivo imaging technology, so as to understand the neurobiological basis of drug addiction and provide theoretical basis for effective treatment measures.

Key words

drug addiction / mechanism / positron emission computed tomography / imaging agent

引用本文

王舒哲, 王雁, 黄芳华, 邱云良. 正电子发射计算机断层显像技术在药物成瘾机制研究中的应用进展. 中国新药杂志, 2021 , 30 (18) : 1661 -1667 .

Shu-zhe WANG, Yan WANG, Fang-hua HUANG, Yun-liang QIU. Application progress of PET in the study of drug addiction mechanism[J]. Chinese Journal of New Drugs, 2021 , 30 (18) : 1661 -1667 .

基金

收起

国家“重大新药创制”科技重大专项资助项目(2018ZX09201017-008)
上海市科委研发公共服务平台资助项目(18DZ2290100)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

吕荣彬, 韩梅, 刘兴党. 人脑功能显像研究药物成瘾的新进展[J]. 国际放射医学核医学杂志, 2009, 33(4): 210-214.

[2]

KANTHAN M, CUMMING P, HOOKER JM, et al. Classics in neuroimaging: imaging the dopaminergic pathway with PET[J]. ACS Chem Neurosci, 2017, 8(9): 1817-1819.

[3]

HEIDBREDER CA, GARDNER EL, XI ZX, et al. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence[J]. Brain Res Rev, 2005, 49(1): 77-105.

[4]

MACH RH, LUEDTKE RR. Challenges in the development of dopamine D2- and D3-selective radiotracers for PET imaging studies[J]. J Labelled Comp Radiopharm, 2018, 61(3): 291-298.

[5]

GALLEZOT JD, BEAVER JD, GUNN RN, et al. Affinity and selectivity of [¹¹C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo[J]. Synapse, 2012, 66(6): 489-500.

[6]

PAYER D, BALASUBRAMANIAM G, BOILEAU I. What is the role of the D3 receptor in addiction? A mini review of PET studies with [¹¹C]-(+)-PHNO[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2014, 52: 4-8.

[7]

PAYER DE, BEHZADI A, KISH SJ, et al. Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [¹¹C]-+-PHNO[J]. Neuropsychopharmacology, 2014, 39(2): 311-318.

[8]

MUKHERJEE J, CONSTANTINESCU CC, HOANG AT, et al. Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies[J]. Synapse, 2015, 69(12): 577-591.

[9]

BONSALL DR, KOKKINOU M, VERONESE M, et al. Single cocaine exposure does not alter striatal pre-synaptic dopamine function in mice: an [¹⁸F]-FDOPA PET study[J]. J Neurochem, 2017, 143(5): 551-560.

[10]

KRYSTAL JH, MATHEW SJ, D'SOUZA DC, et al. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists[J]. CNS Drugs, 2010, 24(8): 669-693.

[11]

TERBECK S, AKKUS F, CHESTERMAN LP, et al. The role of metabotropic glutamate receptor 5 in the pathogenesis of mood disorders and addiction: combining preclinical evidence with human Positron Emission Tomography (PET) studies[J]. Front Neurosci, 2015, 9: 86.

[12]

MILELLA MS, MARENGO L, LARCHER K, et al. Limbic system mGluR5 availability in cocaine dependent subjects: a high-resolution PET [(11)C]ABP688 study[J]. Neuroimage, 2014, 98: 195-202.

[13]

KALIVAS PW. The glutamate homeostasis hypothesis of addiction[J]. Nat Rev Neurosci, 2009, 10(8): 561-572.

[14]

BIRD MK, REID CA, CHEN F, et al. Cocaine-mediated synaptic potentiation is absent in VTA neurons from mGlu5-deficient mice[J]. Int J Neuropsychopharmacol, 2010, 13(2): 133-141.

[15]

DE LAAT B, WEERASEKERA A, LEURQUIN-STERK G, et al. Glutamatergic biomarkers for cocaine addiction: a longitudinal study using MR spectroscopy and mGluR5 PET in self-administering rats[J]. J Nucl Med, 2018, 59(6): 952-959.

[16]

XU C, ZHANG W, RONDARD P, et al. Complex GABAB receptor complexes: how to generate multiple functionally distinct units from a single receptor[J]. Front Pharmacol, 2014, 5: 12.

[17]

RAVAN S, MARTINEZ D, SLIFSTEIN M, et al. Molecular imaging in alcohol dependence[J]. Handb Clin Neurol, 2014, 125: 293-311.

[18]

LINGFORD-HUGHES AR, WILSON SJ, CUNNINGHAM VJ, et al. GABA-benzodiazepine receptor function in alcohol dependence: a combined ¹¹C-flumazenil PET and pharmacodynamic study[J]. Psychopharmacology, 2005, 180(4): 595-606.

[19]

LINGFORD-HUGHES A, REID AG, MYERS J, et al. A [¹¹C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced α5 benzodiazepine receptors in limbic regions[J]. J Psychopharmacol, 2012, 26(2): 273-281.

[20]

MOELLER SJ, LONDON ED, NORTHOFF G. Neuroimaging markers of glutamatergic and GABAergic systems in drug addiction: Relationships to resting-state functional connectivity[J]. Neurosci Biobehav Rev, 2016, 61: 35-52.

[21]

STOKES PR, MYERS JF, KALK NJ, et al. Acute increases in synaptic GABA detectable in the living human brain: a [¹¹C]Ro15-4513 PET study[J]. Neuroimage, 2014, 99: 158-165.

[22]

LINGFORD-HUGHES A, MYERS J, WATSON B, et al. Using [(11)C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism[J]. Neuroimage, 2016, 132: 1-7.

[23]

BRUIJNZEEL AW. Kappa-opioid receptor signaling and brain reward function[J]. Brain Res Rev, 2009, 62(1): 127-146.

[24]

CROWLEY NA, KASH TL. Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2015, 62: 51-60.

[25]

MARTINEZ D, SLIFSTEIN M, MATUSKEY D, et al. Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study[J]. Neuropsychopharmacology, 2019, 44(10): 1720-1727.

[26]

ZHENG MQ, NABULSI N, KIM SJ, et al. Synthesis and evaluation of ¹¹C-LY2795050 as a κ-opioid receptor antagonist radiotracer for PET imaging[J]. J Nucl Med, 2013, 54(3): 455-463.

[27]

ZHENG MQ, KIM SJ, HOLDEN D, et al. An improved antagonist radiotracer for the κ-opioid receptor: synthesis and characterization of (11)C-LY2459989[J]. J Nucl Med, 2014, 55(7): 1185-1191.

[28]

LI SY, CAI ZX, ZHENG MQ, et al. Novel ¹⁸F-labeled κ-opioid receptor antagonist as PET radiotracer: synthesis and in vivo evaluation of ¹⁸F-LY2459989 in nonhuman primates[J]. J Nucl Med, 2018, 59(1): 140-146.

[29]

CECCARINI J, KUEPPER R, KEMELS D, et al. ¹⁸F MK-9470 PET measurement of cannabinoid CB₁ receptor availability in chronic Cannabis users[J]. Addict Biol, 2015, 20(2): 357-367.

[30]

HIRVONEN J, GOODWIN RS, LI CT, et al. Reversible and regionally selective downregulation of brain cannabinoid CB₁ receptors in chronic daily Cannabis smokers[J]. Mol Psychiatry, 2012, 17(6): 642-649.

[31]

HIRVONEN J, ZANOTTI-FREGONARA P, UMHAU JC, et al. Reduced cannabinoid CB₁ receptor binding in alcohol dependence measured with positron emission tomography[J]. Mol Psychiatry, 2013, 18(8): 916-921.

[32]

MCHUGH PC, BUCKLEY DA. The structure and function of the dopamine transporter and its role in CNS diseases[J]. Vitam Horm, 2015, 98: 339-369.

[33]

RINNE JO, LAIHINEN A, NÅGREN K, et al. PET Examination of the monoamine transporter with [¹¹C]β-CIT and [¹¹C]β-CFT in early Parkinson's disease[J]. Synapse, 1995, 21(2): 97-103.

[34]

SHI J, ZHAO LY, COPERSINO ML, et al. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users[J]. Eur J Pharmacol, 2008, 579(1-3): 160-166.

[35]

VILLEMAGNE V, YUAN J, WONG DF, et al. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from[¹¹C]WIN-35, 428 positron emission tomography studies and direct in vitro determinations[J]. J Neurosci, 1998, 18(1): 419-427.

[36]

DING YS, FOWLER JS, VOLKOW ND, et al. Chiral drugs: comparison of the pharmacokinetics of [¹¹C]d-threo and l-threo-methylphenidate in the human and baboon brain[J]. Psychopharmacology (Berl), 1997, 131(1): 71-78.

[37]

LIU Y, HAN M, LIU X, et al. Dopamine transporter availability in heroin-dependent subjects and controls: longitudinal changes during abstinence and the effects of Jitai tablets treatment[J]. Psychopharmacology (Berl), 2013, 230(2): 235-244.

[38]

LIANG CS, HO PS, YEN CH, et al. Reduced striatal dopamine transporter density associated with working memory deficits in opioid-dependent male subjects: a SPECT study[J]. Addict Biol, 2016, 21(1): 196-204.

[39]

[40]

LOGAN J, VOLKOW ND, FOWLER JS, et al. Concentration and occupancy of dopamine transporters in cocaine abusers with [¹¹C]cocaine and PET[J]. Synapse, 1997, 27(4): 347-356.

[41]

VOLKOW ND, WANG GJ, FOWLER JS, et al. Cocaine uptake is decreased in the brain of detoxified cocaine abusers[J]. Neuropsychopharmacology, 1996, 14(3): 159-168.

[42]

PETER D, LIU Y, STERNINI C, et al. Differential expression of two vesicular monoamine transporters[J]. J Neurosci, 1995, 15(9): 6179-6188.

[43]

TAKAHASHI N, MINER LL, SORA I, et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity[J]. PNAS, 1997, 94(18): 9938-9943.

[44]

BOILEAU I, HOULE S, RUSJAN PM, et al. Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+) [¹¹C] DTBZ study in humans[J]. Synapse, 2010, 64(6): 417-420.

[45]

NARENDRAN R, LOPRESTI BJ, MARTINEZ D, et al. In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers[J]. Am J Psychiatry, 2012, 169(1): 55-63.

[46]

JOHANSON CE, FREY KA, LUNDAHL LH, et al. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers[J]. Psychopharmacology (Berl), 2006, 185(3): 327-338.

[47]

CHEN MK, GUILARTE TR. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair[J]. Pharmacol Ther, 2008, 118(1): 1-17.

[48]

LEE CT, LEHRMANN E, HAYASHI T, et al. Gene expression profiling reveals distinct cocaine-responsive genes in human fetal CNS cell types[J]. J Addict Med, 2009, 3(4): 218-226.

[49]

NARENDRAN R, LOPRESTI BJ, MASON NS, et al. Cocaine abuse in humans is not associated with increased microglial activation: an 18-kDa translocator protein positron emission tomography imaging study with [¹¹C]PBR28[J]. J Neurosci, 2014, 34(30): 9945-9950.

[50]

SNIDER SE, HENDRICK ES, BEARDSLEY PM. Glial cell modulators attenuate methamphetamine self-administration in the rat[J]. Eur J Pharmacol, 2013, 701(1-3): 124-130.

[51]

ATTARZADEH-YAZDI G, AREZOOMANDAN R, HAGHPARAST A. Minocycline, an antibiotic with inhibitory effect on microglial activation, attenuates the maintenance and reinstatement of methamphetamine-seeking behavior in rat[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2014, 53: 142-148.

[52]

WORLEY MJ, SWANSON AN, HEINZERLING KG, et al. Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study[J]. Drug Alcohol Depend, 2016, 162: 245-250.

[53]

THOMAS DM, WALKER PD, BENJAMINS JA, et al. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation[J]. J Pharmacol Exp Ther, 2004, 311(1): 1-7.

[54]

BOWYER JF, ROBINSON B, ALI S, et al. Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure[J]. Synapse, 2008, 62(3): 193-204.

[55]

MIZRAHI R, RUSJAN PM, KENNEDY J, et al. Translocator protein (18 kDa) polymorphism (rs6971) explains in-vivo brain binding affinity of the PET radioligand [(18)F]-FEPPA[J]. J Cereb Blood Flow Metab, 2012, 32(6): 968-972.

[56]

RATHITHARAN G, TRUONG J, TONG J, et al. Microglia imaging in methamphetamine use disorder: a positron emission tomography study with the 18 kDa translocator protein radioligand [F-18]FEPPA[J]. Addict Biol, 2021, 26(1): e12876.

[57]

PALLAVICINI GJ, MASSARDO VT, ARANCIBIA SP, et al. Behavior of brain perfusion with SPECT tomography 99mTc ethylene dicysteine (ECD) in alcohol and cocaine dependents during abstinence[J]. Rev Esp Med Nucl, 2002, 21(6): 410-416.

[58]

DANOS P, KASPER S, GRÜNWALD F, et al. Pathological regional cerebral blood flow in opiate-dependent patients during withdrawal: a HMPAO-SPECT study[J]. Neuropsychobiology, 1998, 37(4): 194-199.

[59]

FIRESTONE LL, GYULAI F, MINTUN M, et al. Human brain activity response to fentanyl imaged by positron emission tomography[J]. Anesth Analg, 1996, 82(6): 1247-1251.

[60]

KRYSTAL JH, WOODS SW, KOSTEN TR, et al. Opiate dependence and withdrawal: preliminary assessment using single photon emission computerized tomography (SPECT)[J]. Am J Drug Alcohol Abuse, 1995, 21(1): 47-63.

[61]

CHILDRESS AR, MOZLEY PD, MCELGIN W, et al. Limbic activation during cue-induced cocaine craving[J]. Am J Psychiatry, 1999, 156(1): 11-18.

[62]

SELL LA, MORRIS JS, BEARN J, et al. Neural responses associated with cue evoked emotional states and heroin in opiate addicts[J]. Drug Alcohol Depend, 2000, 60(2): 207-216.

[63]

LONDON ED, SIMON SL, BERMAN SM, et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers[J]. Arch Gen Psychiatry, 2004, 61(1): 73-84.

[64]

WU JC, KLEIN EA, BELL KM, et al. 361. A PET study of FDG metabolism in abstaining cocaine addicts[J]. Biol Psychiat, 1996, 39(7): 607-607.

[65]

VOLKOW ND, CHANG L, WANG GJ, et al. Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers[J]. Am J Psychiatry, 2001, 158(3): 383-389.

2021年第30卷第18期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-30
出版时间：2021-09-30

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2021-06-24

基金

国家“重大新药创制”科技重大专项资助项目(2018ZX09201017-008)

上海市科委研发公共服务平台资助项目(18DZ2290100)

作者信息

¹上海工程技术大学化学化工学院，上海　201620

²中国医药工业研究总院国家上海新药安全评价研究中心，上海　201203

³国家药品监督管理局药品审评中心，北京　100038

通讯作者:

黄芳华，女，博士，主要从事新药药理毒理审评工作。联系电话：（010）85243169，E-mail：huangfh@cde.org.cn。

邱云良，男，研究员，主要从事新药临床前评价研究。E-mail：ylqiu@ncdser.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322906749501571376

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT